Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of NC-2800 in Major Depressive Disorder
jRCT2031250477Phase 2Recruiting
- Sponsor
- Nippon Chemiphar
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing NC-2800 group with Placebo group (2 arms). Primary endpoint: Primary depression evaluation items. Started Jan 2026; status: recruiting.
02
Drugs
NC-2800
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031250477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250477.